Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 865,000 | 952,000 | 426,000 | 570,000 | 928,000 |
| Receivables | 2,228,000 | 2,101,000 | 2,134,000 | 2,076,000 | 1,970,000 |
| Inventories | 2,484,000 | 2,404,000 | 2,250,000 | 2,050,000 | 1,867,000 |
| Other current assets | 622,000 | 740,000 | 773,000 | 712,000 | 731,000 |
| TOTAL | $6,514,000 | $6,504,000 | $5,886,000 | $5,704,000 | $5,760,000 |
| Non-Current Assets | |||||
| PPE Net | 2,859,000 | 2,635,000 | 2,534,000 | 2,478,000 | 2,446,000 |
| Intangibles | 20,390,000 | 19,457,000 | 19,722,000 | 19,329,000 | 18,822,000 |
| Other Non-Current Assets | 5,372,000 | 5,445,000 | 5,460,000 | 5,382,000 | 5,442,000 |
| TOTAL | $28,621,000 | $27,537,000 | $27,716,000 | $27,189,000 | $26,710,000 |
| Total Assets | $35,136,000 | $34,043,000 | $33,601,000 | $32,892,000 | $32,469,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 531,000 | 513,000 | 559,000 | 510,000 | 20,000 |
| Accounts payable and accrued liabilities | 942,000 | 929,000 | 899,000 | 868,000 | 862,000 |
| Accrued Expenses | 2,646,000 | 2,255,000 | 2,164,000 | 1,918,000 | 2,160,000 |
| Other current liabilities | 814,000 | 882,000 | 940,000 | 787,000 | 761,000 |
| TOTAL | $4,933,000 | $4,579,000 | $4,562,000 | $4,083,000 | $3,803,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 8,571,000 | 8,386,000 | 8,494,000 | 8,495,000 | 8,915,000 |
| Other Non-Current Liabilities | 1,967,000 | 1,858,000 | 1,926,000 | 1,995,000 | 2,035,000 |
| TOTAL | $10,672,000 | $10,335,000 | $10,555,000 | $10,700,000 | $11,094,000 |
| Total Liabilities | $15,606,000 | $14,914,000 | $15,116,000 | $14,783,000 | $14,896,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,467,096 | 1,464,983 | 1,464,223 | 1,437,698 | 1,434,780 |
| Common Shares | 17,000 | 17,000 | 17,000 | 17,000 | 17,000 |
| Retained earnings | 819,000 | 315,000 | -189,000 | -450,000 | -750,000 |
| Other shareholders' equity | 298,000 | 475,000 | 467,000 | 437,000 | 268,000 |
| TOTAL | $19,530,000 | $19,129,000 | $18,485,000 | $18,109,000 | $17,573,000 |
| Total Liabilities And Equity | $35,136,000 | $34,043,000 | $33,601,000 | $32,892,000 | $32,469,000 |